<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456390</url>
  </required_header>
  <id_info>
    <org_study_id>GCF-023</org_study_id>
    <nct_id>NCT01456390</nct_id>
  </id_info>
  <brief_title>Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents</brief_title>
  <official_title>A Prospective Evaluation of Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation in the eyes of subjects with one prior trabeculectomy on one to three ocular
      hypotensive medications of the intraocular pressure (IOP) lowering effect of two iStent
      stents in combination with one iStent supra stent and a postoperative prostaglandin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation in the eyes of subjects with one prior trabeculectomy on one to three ocular
      hypotensive medications of the intraocular pressure (IOP) lowering effect of two iStent
      stents in combination with one iStent supra stent and a postoperative prostaglandin.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects observed at Month 12 who experience a mean medicated diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP</measure>
    <time_frame>12 Months</time_frame>
    <description>Primary: Subjects observed at the Month 12 visit who experience a mean diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP, had no glaucoma surgical procedures (incisional or laser surgery prior to the 12 month visit), and no postoperative procedure to reposition or remove the stent prior to the 12 month visit, or additional ocular hypotensive medications within 4 weeks of the Month 12 visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal IOP &lt; 18mm Hg</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary: Subjects observed at the Month 12 visit who experience a mean diurnal IOP &lt; 18 mmHg, had no glaucoma surgical procedures (incisional or laser surgery) prior to the 12 month visit, and no postoperative procedure to reposition or remove the stent prior to the 12 month visit or additional ocular hypotensive medications within 4 weeks of the Month 12 visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety/adverse event monitoring</measure>
    <time_frame>0-61 months</time_frame>
    <description>Rate of ocular adverse events through 61 months
Findings from IOP, best corrected visual acuity, visual field, specular microscopy measurements
Findings from slit-lamp, fundus and gonioscopic examinations</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>iStent and iStent supra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Implantation of two iStent devices and one iStent supra device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent and iStent supra</intervention_name>
    <description>Implantation of two iStent devices and one iStent supra device</description>
    <arm_group_label>iStent and iStent supra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phakic patients or pseudophakic patients with posterior chamber intraocular lenses
             (PC-IOLs)

          -  Open-angle glaucoma (including pseudoexfoliative)

        Exclusion Criteria:

          -  Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs)

          -  Prior ALT

          -  Prior SLT within 90 days of screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilit A Voskanyan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.V. Malayan Ophthalmological Center, Yerevan, Armenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.V. Malayan Ophthalmological Center</name>
      <address>
        <city>Yerevan</city>
        <zip>0001</zip>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open angle glaucoma</keyword>
  <keyword>Prior trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

